Vitrase Journal Ad Lacks Risk Information, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The violative ad for the spreading agent omits warnings, the Division of Drug Marketing, Advertising & Communications states.
You may also be interested in...
Catching DDMAC's Eye: Leaving Out Risk Information Proves Risky Practice For ISTA
ISTA receives a second warning letter from FDA in just over a year for promotional material that omits risk information for its lead ophthalmic product.
Catching DDMAC's Eye: Leaving Out Risk Information Proves Risky Practice For ISTA
ISTA receives a second warning letter from FDA in just over a year for promotional material that omits risk information for its lead ophthalmic product.
WLF’s “DDMAC Watch” Objects To Vitrase Ad Division Letter
Including the full risk information in the “brief summary” portion of promotional materials is sufficient, Washington Legal Foundation says.